GET DAILY SIGNALSKORU Medical Systems (KRMD) Earnings Preview: Watching for Continued Momentum in Q3 2026
Key Takeaways
- KORU Medical Systems (KRMD) is scheduled to report third quarter 2026 results on Tuesday, November 10, after the market close, followed by a conference call at 4:30 p.m. ET.
- Wall Street consensus points to a net loss of about $0.02 per share on revenue of roughly $11.33 million, up about 8.9% year over year.
- KRMD has topped earnings per share (EPS) estimates in every quarter over the past two years, a notable consistency streak heading into this report.
- Second quarter 2026 showed solid momentum, with EPS of $0.01 beating the -$0.02 consensus and revenue of $12.05 million clearing the $11.62 million estimate.
- Investors will focus on subcutaneous infusion demand, gross margin trends, and any update to full-year guidance.
Earnings Context and Why It Matters
KORU Medical Systems develops, manufactures, and commercializes large-volume subcutaneous infusion solutions, including its FREEDOM Syringe Infusion System used for at-home drug delivery. This quarterly report matters because it offers insight into demand from both pharmaceutical partners and patients adopting subcutaneous therapies, a segment that has supported steady revenue growth. The company has also posted a long run of EPS beats, which has helped shape investor expectations. Coming off a stronger-than-expected second quarter, the third-quarter update will show whether that momentum is sustainable and whether management is on track to narrow losses toward profitability. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Earnings Expectations
Analysts expect KORU Medical to report a net loss of approximately $0.02 per share for the third quarter of 2026, the period ended September 30, 2026. The consensus revenue estimate stands at roughly $11.33 million, which would represent an increase of about 8.9% from the prior-year quarter.
Those expectations follow a strong second quarter, when the company posted EPS of $0.01 against a -$0.02 consensus and revenue of $12.05 million versus the $11.62 million estimate. Over the past two years, KRMD has exceeded EPS expectations 100% of the time and topped revenue estimates in most quarters. Key metrics to watch include gross margin, operating expense discipline, and any commentary on new customer activations or regulatory milestones tied to its infusion platform.
Market Reaction and Investor Sentiment
Sentiment heading into the print has been cautiously optimistic, reflecting KORU Medical's track record of exceeding EPS estimates and its recent revenue acceleration. The stock tends to be sensitive around earnings, with meaningful single-day moves following prior reports. Key risk factors include any miss on revenue growth, a wider-than-expected loss, or softer guidance, any of which could pressure shares given the company's still-negative earnings profile. Conversely, another beat combined with constructive commentary on the commercial pipeline could reinforce confidence in the path toward profitability. Investors will also weigh how the results compare with the company's own outlook and recent cost-reduction efforts.
Forward Outlook and Key Factors to Monitor
Looking ahead, investors should watch whether KORU Medical reaffirms or adjusts its full-year guidance, as any revision will set the tone for the remainder of 2026. Demand signals matter most: commentary on new pharmaceutical partnerships, customer adoption of large-volume subcutaneous infusion, and international expansion will indicate whether the recent revenue growth is durable.
Margin trends are another key area. The company has been working to improve gross margin and manage operating expenses, so any evidence of progress toward breakeven or reduced cash burn is likely to draw attention. Supply chain costs and pricing dynamics within its infusion product lines are also worth monitoring.
Finally, broader industry conditions in subcutaneous drug delivery and medical technology spending could influence near-term results. As more therapies shift toward at-home and self-administered delivery, KORU Medical's positioning in that market remains a central part of the long-term narrative, though execution against guidance will ultimately drive investor confidence. From what I see, this consistency in beats makes the upcoming print particularly worth following.
Integrating AI Tools Into Earnings Analysis
In preparing for reports like this one from KRMD, I often turn to Tickeron’s AI Screener to quickly filter healthcare names by fundamentals, technical patterns, and recent performance. It helps surface comparable setups and confirm whether the momentum seen in recent quarters stands out relative to peers, giving a clearer picture without spending hours on manual checks.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Aroon Indicator for KRMD shows an upward move is likely
KRMD's Aroon Indicator triggered a bullish signal on November 10, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 167 similar instances where the Aroon Indicator showed a similar pattern. In 144 of the 167 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 48 of 59 cases where KRMD's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
The Moving Average Convergence Divergence (MACD) for KRMD just turned positive on October 12, 2026. Looking at past instances where KRMD's MACD turned positive, the stock continued to rise in 37 of 47 cases over the following month. The odds of a continued upward trend are 79%.
KRMD moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for KRMD crossed bullishly above the 50-day moving average on November 04, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 80%.
Following a +6.60% 3-day Advance, the price is estimated to grow further. Considering data from situations where KRMD advanced for three days, in 178 of 227 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on KRMD as a result. In 96 of 112 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KRMD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
KRMD broke above its upper Bollinger Band on October 23, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 7 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.904) is normal, around the industry mean (4.964). KRMD has a moderately low P/E Ratio (-77.250) as compared to the industry average of (40.591). Projected Growth (PEG Ratio) (1.770) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (3.292) is also within normal values, averaging (56.876).
The Tickeron PE Growth Rating for this company is 18 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating fairly steady price growth. KRMD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 90 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KRMD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company, which engages in the design, manufacture, and market of proprietary medical devices
Industry PharmaceuticalsOther
Advertisement